Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian Cancer

August 3, 2021 updated by: Rutie Yin, West China Second University Hospital

Phase III Clinical Trial of Intravenous Paclitaxel Plus Intraperitoneal Cisplatin for Neo-adjuvant Chemotherapy in Patients With Advanced Ovarian Cancer

To test the effect of intravenous paclitaxel plus intraperitoneal cisplatin for neo-adjuvant chemotherapy in patients with advanced ovarian cancer, the investigators conducted a phase III single arm clinical trial. Included patients will receive interval debulking surgery after 2-6 cycles neoadjuvant chemotherapy based on the clinical judgment of the gynecologic oncologist. Six cycles of chemotherapy will conducted after surgery. And the neoadjuvant chemotherapy is as follows: paclitaxel 135 mg/m2 i.v. and cisplatin 75 mg/m2 i.p. on day 1. The primary end point is optimal debulking rates. the investigators also will evaluate effect on parameters of volume of ascites, tumor size, duration of surgery, hemorrhage, hospitalizations and postoperative complication etc. After comparing with data published online, the investigators will try to find out if paclitaxel i.v. plus cisplatin i.p. is a superior neoadjuvant chemotherapy for advanced ovarian carcinoma.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

  1. BACKGROUND AND INTRODUCTION Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancy in the developed world with the majority of women presenting with stage III/IV disease. Most patients with advanced-stage cancer will eventually experience recurrence and die as a result of the disease. Therefore, more effective therapies are needed in the treatment of this aggressive cancer.

    After the results of the Gynecologic Oncology Group trial (GOG-152) (NCT00002568) the investigatorsre published, interval debulking surgery was no longer recommended for patients in whom optimal cytoreduction was not achieved despite a maximal effort at primary debulking surgery[1]. The use of neoadjuvant chemotherapy (NACT) before a definitive debulking attempt is increasingly used in advanced EOC based on two RCTs (EORTC55971 and CHORUS) which demonstrated non-inferiority and lothe investigatorsr perioperative morbidity compared with primary surgery follothe investigatorsd by chemotherapy[2, 3]. But what is the preferred chemotherapy regimen for women who will receive NACT is still a question[4].

    Evidence from the peritoneal dialysis literature suggests that the peritoneal permeability of a number of hydrophilic anticancer drugs may be considerably less than plasma clearance. Pharmacokinetic calculations indicate that such drugs administered i.p.(intraperitoneal chemotherapy,i.p.) in large volumes are expected to maintain a significantly greater concentration in the peritoneal space than in the plasma. Prior studies have reported on the pharmacologic advantage of delivering cisplatin i.p., with a 20-fold higher concentration in the i.p. space compared with that measured in plasma after i.v. administration[5]. This concentration difference offers a potentially exploitable biochemical advantage in the treatment of patients with presumed microscopic residual ovarian cancer confined to the peritoneal cavity[6]. In addition, i.p. therapy allows for continuous and prolonged exposure of high drug concentrations with lothe investigatorsr peak plasma levels over time[7].

    Three randomized clinical trials (RCTs) and a meta-analysis had demonstrated improved survival for women with stage III EOC who received a combination of i.v. and i.p. chemotherapy following optimal, primary debulking surgery[8-10]. GOG 172 confirmed a continued benefit for women who had received the experimental arm[11]. OV21/PETROC proved in women with stage IIIC or IVA EOC treated with NACT and optimal debulking surgery, i.p. carboplatin-based chemotherapy is the investigatorsll tolerated and associated with an improved PD9 (9-month progressive disease rate) compared with i.v. carboplatin-based chemotherapy. But there is no RCT focused on the role of i.p. in NACT[12].

    From the retrospective data in our institution (not published yet), compared with intravenous paclitaxel plus carboplatin, intravenous paclitaxel plus i.p. cisplatin shothe investigatorsd more effective in NACT, and side effects like nausea and vomiting are acceptable and manageable, moreover, with lothe investigatorsr bone marrow suppression rate. To determine the role of i.p. cisplatin in NACT the investigators desiged a RCT to compare optimal debulking rates and progression-free survival (PFS) in women with stage IIIc or IV epithelial ovarian carcinoma after treated with NACT using intravenous paclitaxel plus carboplatin and intravenous paclitaxel plus i.p. cisplatin.

  2. OBJECTIVES OF THE TRIAL To test effect of intravenous paclitaxel plus intraperitoneal cisplatin for neo-adjuvant chemotherapy in patients with advanced ovarian cancer

  3. TRIAL DESIGN. Treatment: paclitaxel 135 mg/m2 i.v. and cisplatin 75 mg/m2 i.p. on day 1

    Principal surgeon:

    Only senior surgeons will be allothe investigatorsd to have the responsibility for the surgery. Each senior surgeon will follow carefully the guideline for surgery.

    Cycle of chemotherapy:

    Surgery may be performed after 2-6 cycles based on the clinical judgment of the gynecologic oncologist. Six cycles of chemotherapy will conducted after surgery.

  4. THERAPEUTIC REGIMENS Interval debulking surgery should be performed within 6 the investigatorseks after course 2-6 in all patients with response or stable disease. If this time limit is not met the patient has to be excluded from this protocol. Follothe investigatorsd by 6 courses of chemotherapy within 3 the investigatorseks after surgery.

    Regimens: paclitaxel 135 mg/m2 i.v. and cisplatin 75 mg/m2 i.p. on day 1

  5. ENDPOINT OF THIS STUDY First stage

Primary end point:

Optimal debulking rates

  • Optimal cytoreduction was defined as largest residual tumor nodule not greater than 1 cm in maximal diameter at the completion of the primary operation.

Secondary end points:

Volume of ascites Tumor size Duration of surgery, hemorrhage, hospitalizations Postoperative complication (infection, venous complications, hospitalization etc.) AEs of chemotherapy

*Upper abdomen surgical procedures the investigatorsre defined as splenectomy, pancreatectomy, gallbladder resection, liver resection, diaphragmatic resection.

Second stage Primary end point Progression free survival (PFS) Secondary end points Overall survival (OS)

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Sichuan
      • Chendu, Sichuan, China, 610041
        • Recruiting
        • West China Second University Hospital of Sichuan University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Preferentially biopsy proven Stage IIIc or IV epithelial ovarian carcinoma, or peritoneal or fallopian tube carcinoma (the presence of metastases outside the pelvis measuring at least 2 cm in diameter (as noted during diagnostic laparoscopy or laparotomy or on computed tomography [CT]),with a low likelihood of achieving cytoreduction to, 1 cm (ideally to no visible disease). Or women who have a high perioperative risk profile.

  2. Fine needle aspiration (FNA) showing an adenocarcinoma and cytopathology from ascites or pleural effusion is acceptable under the following conditions:

    the patient has a pelvic (ovarian) mass, AND omental cake or other metastasis larger than 2 cm in the upper abdomen and/or regional lymphnode metastasis irrespective of size or stage IV AND serum CA125/CEA ratio > 25. If the serum CA125/CEA ratio is < 25, a barium enema (or colonoscopy) and gastroscopy (or radiological examination of the stomach) should be negative for the presence of a primary tumor (< 6 weeks before randomization), and normal mammography (< 6 weeks).

  3. WHO performance status of 0, 1, or 2.
  4. No other serious disabling diseases contraindicating for cytoreductive surgery or platin based chemotherapy.
  5. No other prior primary malignancies, except for carcinoma in situ of the cervix and basal carcinoma of the skin.
  6. No clinical evidence of brain or leptomeningeal metastases.
  7. Adequate hematological, renal and hepatic function to permit platin-paclitaxel based chemotherapy: WBC > 3.0 x 109/L, N >1.5 x 109/L, platelets > 100 x 109/L, serum creatinine < 1.25 x upper normal range, serum bilirubin < 1.25 x upper normal range.
  8. Absence of any psychological, familial, sociological or geographical condition potentially preventing compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before registration in the trial.
  9. Before patient registration/randomization, informed consent must be obtained and documented according to national and local regulatory requirements and the local rules followed in the institution.

Exclusion Criteria:

  1. serious disabling diseases that would contraindicate primary cytoreductive surgery or platinumbased chemotherapy
  2. mucinous or borderline histology, extensive intra-abdominal adhesions, bowel obstruction or unresolved>grade 2 peripheral neuropathy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm i.p
paclitaxel i.v. and cisplatin i.p.
Drug: cisplatin i.p.
paclitaxel 135 mg/m2 i.v. and cisplatin 75 mg/m2 i.p. on day 1
Other Names:
  • intraperitoneal cisplatin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Optimal debulking rates
Time Frame: up to 18 weeks
Optimal cytoreduction was defined as largest residual tumor nodule not greater than 1 cm in maximal diameter at the completion of the primary operation.
up to 18 weeks
PFS
Time Frame: Progression free survival (PFS) will be measured from the date enrollment to the first documented date of progression, or death, whichever occurs first, assessed up to 36 months.
Progression free survival
Progression free survival (PFS) will be measured from the date enrollment to the first documented date of progression, or death, whichever occurs first, assessed up to 36 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
OS
Time Frame: Overall survival (OS) will be measured from the date of enrollment to the date of death, whatever the cause, assessed up to 36 months.
Overall survival
Overall survival (OS) will be measured from the date of enrollment to the date of death, whatever the cause, assessed up to 36 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

West China Second University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 4, 2021

Primary Completion (Anticipated)

May 1, 2023

Study Completion (Anticipated)

March 1, 2024

Study Registration Dates

First Submitted

April 27, 2021

First Submitted That Met QC Criteria

May 7, 2021

First Posted (Actual)

May 13, 2021

Study Record Updates

Last Update Posted (Actual)

August 10, 2021

Last Update Submitted That Met QC Criteria

August 3, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • WestChinaSUH2020076

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neoadjuvant Chemotherapy

Clinical Trials on cisplatin i.p.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe